MARKETSPERPSLIVE73
Cash
Portfolio
TrendingElectionsPoliticsCultureSportsCryptoCommoditiesClimateEconomicsMentions

Finance

Tech & Science
PredictLive73AccountSocial
Product
Kalshi ProPerpetual FuturesMarketsIncentive programInstitutionsAPI & developers
Company
AboutKalshi ResearchBlogCareersPolicy CenterBrand Kit
Help
Help CenterFAQFee scheduleTrading hoursRegulatoryTrust Center
© 2026 Kalshi Inc. · All rights reserved
PrivacyData Terms of ServiceTrading ProhibitionsFAQ for Finance Professionals
Trading on Kalshi involves risk and may not be appropriate for all. Members risk losing their cost to enter any transaction, including fees. You should carefully consider whether trading on Kalshi is appropriate for you in light of your investment experience and financial resources. Any trading decisions you make are solely your responsibility and at your own risk. Information is provided for convenience only on an "AS IS" basis. Past performance is not necessarily indicative of future results. Kalshi is subject to U.S. regulatory oversight by the CFTC.
TrendingElectionsPoliticsCultureSportsCryptoCommoditiesClimateEconomicsMentions

Finance

Tech & Science

Biotech

All markets
Public Companies Hub
Companies
Indices
Industries
Biotech
Compute
Markets
Biotech

FDA decision: BBP-418 by Ml Bio Solutions Inc. (this year)

Yes
1.07x
No
6.29x
$831 vol1 market
Biotech

FDA decision: Ivonescimab by Summit Therapeutics (this year)

Yes
1.79x
No
1.86x
$4,988 vol1 market
Biotech

FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (this year)

Yes
1.22x
No
3.52x
$950 vol1 market
Biotech

FDA decision: Venglustat by Sanofi (this year)

Yes
1.16x
No
1.19x
$452 vol1 market
Biotech

FDA decision: Saroglitazar by Zydus Therapeutics (this year)

Yes
1.46x
No
1.01x
$351 vol1 market
Biotech

FDA decision: Rusfertide by Protagonist Therapeutics (this year)

Yes
1.08x
No
5.90x
$1,640 vol1 market
Biotech

FDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (this year)

Yes
1.20x
No
3.66x
$468 vol1 market
Biotech

FDA decision: Brepocitinib by Priovant Therapeutics (this year)

Yes
1.22x
No
3.52x
$6,056 vol1 market
Biotech

FDA decision: bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN) by Gilead Sciences (this year)

Yes
1.04x
No
7.85x
$703 vol1 market
Biotech

FDA decision: Bepirovirsen by GlaxoSmithKline (this year)

Yes
1.29x
No
2.98x
$942 vol1 market